Pliant Therapeutics (PLRX) Non Operating Interest Expenses (2022 - 2025)

Pliant Therapeutics (PLRX) has reported Non Operating Interest Expenses for 4 consecutive years, with $136000.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Non Operating Interest Expenses fell 83.69% year-over-year to $136000.0 in Q4 2025; TTM through Jun 2026 was $951000.0, a 71.35% decrease from a year earlier, with the FY2025 full-year figure at $2.6 million, down 15.38% from the prior year.
• Non Operating Interest Expenses was $136000.0 for Q4 2025 at Pliant Therapeutics, down from $815000.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $877000.0 in Q3 2024 and troughed at $136000.0 in Q4 2025.
• A 4-year average of $509466.7 and a median of $321000.0 in 2023 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses surged 176.66% in 2024 and tumbled 83.69% in 2025, its largest moves.
• Over 4 years, Non Operating Interest Expenses stood at $317000.0 in 2022, then advanced by 1.26% to $321000.0 in 2023, then surged by 159.81% to $834000.0 in 2024, then plunged by 83.69% to $136000.0 in 2025.
• The last three Non Operating Interest Expenses figures came in at $136000.0 (Q4 2025), $815000.0 (Q3 2025), and $809000.0 (Q2 2025), per Business Quant data.